Our focus on innovation driven by science and technology
means that we're constantly exploring
new approaches to the challenges we face.
At Wave, RNA technology is core to our business,
and we are looking to work with people who share our commitment to patients.
With capabilities that are complementary, so that together
we can access new areas of disease biology and unlock new targets.
Our culture, being ambitious for patients, is embedded in who we are.
So we go after the biggest challenges to make a difference for them.
And this is how we came to work together.
Our PRISM platform pairs
best in class oligonucleotide chemistry
with multiple RNA-targeting modalities
such as silencing with siRNA or antisense,
editing and splicing.
The challenge was that the advancement of our technology
had outpaced the number of addressable disease targets.
This is where GSK came in.
We have a strong focus on genetics and genomics,
and the majority of our specialty pipeline is now backed by human genetic evidence.
And this is opening the door to explore
a variety of modalities
and deliver potential new medicines to patients.
One area where Wave and GSK may have
a significant impact is in RNA editing.
RNA editing
is a new modality being pioneered at Wave
and it can address diseases with no or suboptimal treatments.
Having the technology to explore multiple forms of RNA editing to create
oligonucleotide therapeutics expands what's possible for patients.
GSK and Wave
collaborate from research to clinical compounds, combining
genetics and genomic expertise with innovative manufacturing.
Partnering with a genetics expert who shares our vision
for the potential of oligonucleotide therapeutics made GSK a perfect fit.
Being in an active innovation hub
like Boston meant our teams have known each other for years,
and a formal collaboration was the natural next step.
We share a commitment to science and a desire to improve patient outcomes.
Science and technology powers everything we do at GSK,
but our people really make our work come to life,
and the relationships we build inside and outside GSK
are helping us to transform drug discovery
and development.
At Wave and GSK,
our people share a common goal
of unlocking the broad potential of oligonucleotide therapeutics.
And we believe that together we can transform science
and transform patients’ lives.